Multi-omics to Predict Responses to Biologics in IBD

计划入组 1,050 人 · 首次发布于 2022 年 9 月 15 日

A Clinical Study to Evaluate the Efficacy of Biologics in SpA

计划入组 40 人 · 首次发布于 2020 年 5 月 22 日

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

计划入组 9 人 · 首次发布于 2014 年 10 月 31 日

Bone-1064

Sepia esculenta bone

QBSAU

Bone Biologics

TANVEX BIOLOGICS CORPORATION

Taiwan

Critical Biologics Corporation

United States

Bone Biologics Files Patent Application for Novel NELL-1 Protein Technology in Spine Fusion

Bone Biologics Doubles Australian Trial Sites for NB1 Spinal Fusion Study, Targets Year-End 2026 Enrollment

XOMA Royalty Corporation to Acquire Turnstone Biologics for $0.34 Per Share Plus Contingent Value Rights